Alternatives to antibiotics

Intensive Care Medicine

Volumn 42, Issue 12, 2016, Pages 2034-2036

  François, Bruno ^a,b   Jafri, Hasan S ^c   Bonten, Marc ^d  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UMR 1092   (France)

^c MEDIMMUNE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MONOCLONAL ANTIBODY; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BACTERIOPHAGE; CROSS INFECTION;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; BACTERIOPHAGES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS;

EID: 84962141546     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4339-y     Document Type: Article

References (17)

1. Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE (1997) Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 39:527–535
2. Allerberger F, Gareis R, Jindrak V, Struelens MJ (2009) Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther 7:1175–1183
3. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33:322–327
4. European Centre for Disease Prevention and Control (2015) Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf. Accessed 11 Feb 2016
5. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA et al (2016) Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 16(2):239–251
6. Timsit JF, Perner A, Bakker J, Bassetti M, Benoit D, Cecconi M et al (2015) Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med 41(4):575–588
7. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT et al (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671
8. Que Y, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33(10):1861–1867
9. Francois B, Luyt CE, Dugard A, Wolff M, Diehl J, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 40(8):2320–2326
10. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6(262):262ra155
11. Berube BJ, Bubeck Wardenburg J (2013) Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 5(6):1140–1166
12. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR et al (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173–2179
13. Sansom C (2015) Phage therapy for severe infections tested in the first multicentre trial. Lancet Infect Dis 15(12):1384–1385
14. Coulter LB, McLean RJ, Rohde RE, Aron GM (2014) Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6(10):3778–3786
15. Shaw KJ, Lehman SM, Smrekar F, Weiss WJ, Pulse M, Morales SP (2015) Efficacy of a bacteriophage cocktail in a Staphylococcus aureus mouse pneumonia model is comparable to vancomycin. Poster presentation, ICAAC/ICC 2015, San Diego
16. Cooper CJ, Denyer SP, Maillard JY (2014) Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett Appl Microbiol 58:118–122
17. Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, Kadioglu A, O’Callaghan C, Clokie MR (2015) Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28(5):353–360